Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
1.700
0.00 (0.00%)
Sep 20, 2024, 4:00 PM EDT - Market closed
Century Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 2.04 | 2.24 | 5.2 | - | - | - |
| Revenue Growth (YoY) | -55.28% | -57.01% | - | - | - | - |
| Cost of Revenue | 95.73 | 92.71 | 97.17 | 75.65 | - | - |
| Gross Profit | -93.68 | -90.48 | -91.97 | -75.65 | - | - |
| Selling, General & Admin | 34.63 | 34.71 | 31.86 | 19.24 | 9.5 | 5.77 |
| Research & Development | - | - | - | - | 39.68 | 14.27 |
| Operating Expenses | 34.63 | 34.71 | 31.86 | 19.24 | 49.18 | 20.03 |
| Operating Income | -128.31 | -125.18 | -123.83 | -94.88 | -49.18 | -20.03 |
| Interest Expense | - | -0.54 | -1.43 | -1.28 | -0.38 | - |
| Interest & Investment Income | 13.82 | 12.68 | 4.42 | 0.38 | 0.7 | 1.21 |
| Other Non Operating Income (Expenses) | -0 | -0.38 | - | - | - | - |
| EBT Excluding Unusual Items | -114.5 | -113.43 | -120.84 | -95.78 | -48.85 | -18.82 |
| Asset Writedown | -12.15 | -16.37 | - | - | - | - |
| Pretax Income | -131.64 | -134.79 | -130.84 | -95.78 | -53.58 | -244.77 |
| Income Tax Expense | -0.26 | 1.88 | 0.09 | 0.04 | - | - |
| Net Income | -131.39 | -136.67 | -130.93 | -95.82 | -53.58 | -244.77 |
| Net Income to Common | -131.39 | -136.67 | -130.93 | -95.82 | -53.58 | -244.77 |
| Shares Outstanding (Basic) | 66 | 59 | 58 | 32 | 7 | 7 |
| Shares Outstanding (Diluted) | 66 | 59 | 58 | 32 | 7 | 7 |
| Shares Change (YoY) | 12.71% | 2.70% | 78.30% | 332.95% | 10.43% | - |
| EPS (Basic) | -1.99 | -2.30 | -2.27 | -2.96 | -7.16 | -36.13 |
| EPS (Diluted) | -1.99 | -2.30 | -2.27 | -2.96 | -7.16 | -36.13 |
| Free Cash Flow | -102.51 | -102.08 | -16.55 | -133.97 | -51.09 | -18.63 |
| Free Cash Flow Per Share | -1.55 | -1.72 | -0.29 | -4.14 | -6.83 | -2.75 |
| Operating Margin | -6286.67% | -5600.94% | -2381.82% | - | - | - |
| Profit Margin | -6437.38% | -6115.12% | -2518.41% | - | - | - |
| Free Cash Flow Margin | -5022.44% | -4567.52% | -318.37% | - | - | - |
| EBITDA | -114.72 | -112.14 | -115.39 | -91.14 | -47.77 | -19.78 |
| D&A For EBITDA | 13.59 | 13.04 | 8.44 | 3.75 | 1.4 | 0.25 |
| EBIT | -128.31 | -125.18 | -123.83 | -94.88 | -49.18 | -20.03 |
Source: S&P Capital IQ. Standard template.
Financial Sources.